The UK government, and UK vice chancellors, are exerting a lot of pressure to increase industrial funding in Universities. So far they haven’t listened at all to suggestions that research and commerce don’t mix well. It is asking too much of human nature to think that judgment about an experiment will not be influenced if you have a financial interest in one outcome rather than another. That is why the best researchers (at least in the biomedical field) avoid industry funding whenever possible: they want their results to be seen as independent.
It is well documented now that clinical trials tend to be distorted when they are funded by the pharmaceutical industry. See, for example, Lexchin, Bero et al,. in the British Medical Journal (2003), and Brennan et al. (2006) in the Journal of the American Medical Association, and the excellent book. The Truth About the Drug Companies, by Marcia Angell.
Brennan’s proposals for reducing this influence were well received on the whole, though they were opposed by a Dr K.J. Meador of Florida. But them Dr Meador’s letter ended with “Financial Disclosures: Dr Meador reported receiving grants from GlaxoSmithKline, Neuropace, SAM Technology, UCB, and the NIH; acting as a consultant to Abbott, Cyberonics, Eisai, GlaxoSmithKline, Neuropace, Novartis, Ortho McNeil, and UCB; obtaining honoraria from GlaxoSmithKline, Ortho McNeil, and UCB; and receiving salary from clinical electrophysiology, patient care, and an endowed chair at the University of Florida.”. Well, there’s a surprise.
It seems that this has dawned on the University of California. Their central administration, according to a report in Nature magazine (July 2007), has attempted to restrict the way the pharmaceutical industry buy favour in academia. The Nature editorial ends thus,
â€œ. . . the latest policy tries to put the brakes on a trend towards heavier reliance on private funding that this fiscal squeeze has unleashed. The universityâ€™s campuses are understandably concerned about their ability to attract funding from all sources so that they can continue to operate at world-class levels. The best course available to them, nonetheless, is to follow the high standards that have recently been set at other academic medical centres, such as those at Stanford University, and to embrace the proposed policy. â€
Quite. It seems that the UK government and UK vice chancellors are going flat out for a policy that is already out of favour at Stanford. They are one step behind again. But then neither are Stanford, Yale and Harvard heading quite so enthusiastically down a path that takes power out of the hands of those who teach and do research.
Of course, Yale still has a Department of Pharmacology. Which is more than UCL has.
Postscript. There is nothing that the quackery industry likes to talk about more than the evils of Big Pharma. What they should remember is that the quackery industry is not only rich, but it is almost 100% fraud. Big Pharma may behave badly at times, but, with on the basis of pure research done largely in universities, they are also the folks who brought you general anaesthetics, antibiotics and all manner of things that have improved and lengthened lives.
- There are some sensible comments about industry funding here. There are always problems, but in some areas they are perhaps not as big as in the biomedical business.